Shanghai Lunsheng Pharmaceutical Technology

Lunsheng Pharma is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company focuses on high-growth therapeutic areas such as obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Its lead programs include multi-agonist small molecules targeting the GLP-1, GIP, and glucagon receptors, aiming to provide oral alternatives to injectable biologics. Lunsheng Pharma leverages its internal R&D capabilities to advance a pipeline of candidates from discovery through clinical proof-of-concept. The company is positioned to address significant unmet medical needs in the global metabolic health market.